D-dimer and CA 125 levels in patients with ovarian cancer during antineoplastic therapy. Prognostic significance for the success of anti-cancer treatment.
In patients with ovarian cancer before they receive chemotherapy, the level of fibrin degradation products (D-dimer), is correlated with the tumor load. In this study, the evolution of D-dimer was compared in patients receiving antineoplastic therapy with the evolution of the disease. The patients could be classified into three groups. In Group 1 (nine patients), both plasma CA 125 (a tumor-associated antigen) and D-dimer remained elevated; the prognosis was always poor. In Group 2 (eight patients), CA 125 and D-dimer decreased simultaneously, complete remission was observed in two patients, and significant residual tumor was observed in the others. In Group 3 (nine patients), despite an important decrease in CA 125, D-dimer remained elevated during therapy. In this group, complete remission was observed in six patients, and three others showed a large decrease in their tumor load. The combination of a decrease in CA 125 levels with a continuous enhanced level of D-dimer during chemotherapy identified a subgroup of patients with a favorable prognosis.
Mirshahi
S S
SS
Laboratoire Sainte Marie, Hôtel Dieu, Paris, France.
Pujade-Lauraine
E
E
Soria
C
C
Mirshahi
M
M
Fretault
J
J
Bernadou
A
A
Soria
J
J
D015295:Antigens, Tumor-Associated, Carbohydrate / Q000378:metabolism*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000378:metabolism*; D006801:Humans; D010051:Ovarian Neoplasms / Q000097:blood* / Q000188:drug therapy; D011237:Predictive Value of Tests; D011379:Prognosis
D015295:Antigens, Tumor-Associated, Carbohydrate; D005338:Fibrin Fibrinogen Degradation Products